All Press Releases
CEO Dorte X. Gram increases holding in Pila Pharma AB
Malmö, July 1, 2022 Pila Pharma AB (publ) announces that CEO Dorte X. Gram on Thursday, June 30, bought 12,700 shares in the company. The shares were purchased at an average price of SEK 3.93. The transaction took place through the company Gram Equity Invest, which she owns together with her son Gustav Hanghøj Gram. Dorte X. Gram is the…
Pila Pharma AB inleder toxikologiska studier
Malmö, 30 juni, 2022 Pila Pharma AB (publ) meddelar att de prekliniska toxikologiska tremånadersstudierna av den aktiva substansen XEN-D0501 har inletts. Pila Pharma förbereder, som tidigare meddelats, en klinisk fas 2b-studie av läkemedelskandidaten XEN-D0501 mot diabetes typ 2. Tidigare har XEN-D0501 utvärderats i både toxikologiska säkerhetsstudier och i kliniska prövningar, i fas 1 och fas 2a, på människor med upp…
Pila Pharma AB initiates toxicological studies
Malmö, June 30, 2022 Pila Pharma AB (publ) announces that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials…